Kliničkopatološka retrospektivna analiza timoma u Srbiji: iskustvo jednog centra

  • Natalija Samardžić Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Dragana Jovanović Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Ljiljana Marković-Denić Clinical Center of Serbia, Faculty of Medicine, Belgrade, Serbia
  • Sanja Šarac University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbi a
  • Vesna Škodrić-Trifunović Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Jelena Stojšić Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Mihailo Stjepanović Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Spasoje Popević Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Branislav Ilić Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Vesna Ćeriman Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Marina Roksandić Milenković Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Milija Gajić Clinical Center of Serbia, Clinic for Pulmonology, Belgrade, Serbia
  • Ivan Soldatović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP180103056S
Ključne reči: timom, dijagnoza, neoplazme, određivanje stadijuma, lečenje, ishod, preživljavanje, srbija

Sažetak


Uvod/Cilj. Timomi su retke bolesti, ali najčešći tumori medijastinuma. Terapijski vodiči su zasnovani na rezultatima analiza retrospektivnih studija. Cilj ove studije je bio da se definišu osnovne kliničke karakteristike obolelih od timoma, terapijski aspekti, preživljavanje i pojava relapsa bolesti. Metode. Ovom retrospektivnom studijom analizirana su 62 bolesnika sa patohistološki verifikovanim timomom u Klinici za plućne bolesti Kliničkog centra Srbije u Beogradu, u periodu od januara 1993. do decembra 2013. Popunjavani su upitnici koji su obuhvatali podatke iz istorije bolesti, fizički pregled bolesnika, nalaze radiografije i/ili kompjuterizovane tomografije grudnog koša, operativne liste i/ili patohistološke nalaze biopsija. Analizirani su klinička slika, terapijski aspekti, preživljavanje i pojava relapsa bolesti. Timomi su klasifikovani prema patohistološkoj klasifikaciji Svetske zdravstvene organizacije i prema Masaoka-Koga sistemu. Rezultati. Više je bilo obolelih žena (54,8%). Najveći broj bolesnika je bio u sedmoj deceniji života (32,3%). Skoro trećina bolesnika je bila asimptomatska (29%), a ostali su imali bar jedan simptom, najčešće kašalj. Najčešći paraneoplastički sindrom bila je miastenija gravis (12,9%). Najčešće je konstatovano prisustvo solitarne promene u grudnom košu (61,3%), tumora većeg od 5 cm (52,5%) i neinvazivnih timoma (52,5%). Većina bolesnika je bila u I stadijumu bolesti (40%), a najčešći terapijski pristup operacija (88,7%). Statistički značajna razlika u preživ­ljavanju konstatovana je kod žena, bolesnika koji su imali solitarni tumor, neinvazivni timom, I stadijum bolesti i bolesnika kojima je učinjena operacija. Dimenzija tumora je bila blizu granice konvencionalnog nivoa značajnosti. Za­klju­čak. Statistički značajni prediktori preživljavanja kod obolelih od timoma su pol, diseminovanost bolesti, invazivnost tumora, klinički stadijum bolesti i operativno lečenje.

Reference

Rea F, Marulli G, Di Chiara F, Schiavon M, Perissinotto E, Breda C et al. Multidisciplinary approach for advanced stage thymic tumors: long-term outcome. Lung Cancer 2011; 72(1): 68–72.

Kondo K. Therapy for thymic epithelial tumors. Gen Thorac Cardiovasc Surg 2014; 62(8): 468–74.

Helm JM, Lavy D, Figueroa-Bodine J, Joseph S. Metastatic Malig-nant Thymoma to the Abdomen: A SEER Database Review and Assessment of Treatment Strategies. World J Oncol 2017; 8(5): 147–50.

Vladislav T, Jain RK, Alvarez R, Mehta RJ, Gökmen-Polar Y, Kesler KA, et al. Extrathoracic metastases of thymic origin: a review of 35 cases. Mod Pathol 2012; 25(3): 370–7.

Travis WB, Brambilla A, Muller-Hermelinck HK, Marx A. Pa-thology and genetics of tumors of the lung, pleura, thymus and heart. In: Travis WB, editor. World Health Organization Clas-sification of tumors. Lyon: IARC Press 2004; p. 146.

Marx A, Ströbel P, Badve SS, Chalabreysse L, Chan JK, Chen G, et al. ITMIG consensus statement on the use of the WHO his-tological classification of thymoma and thymic carcinoma: re-fined definitions, histological criteria, and reporting. J Thorac Oncol. 2014; 9(5): 596–611.

Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S. ESMO Guidelines Committee.Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and fol-low-up. Ann Oncol 2015; 26(Suppl 5): v40–55.

Safieddine N, Liu G, Cuningham K, Ming T, Hwang D, Brade A, et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol 2014; 9(7): 1018–22.

Nakajima J, Okumura M, Yano M, Date H, Onuki T, Haniuda M, et al. Myasthenia gravis with thymic epithelial tumour: a retro-spective analysis of a Japanese database. Eur J Cardiothorac Surg 2016; 49(5): 1510–5.

Nazarbaghi S, Amiri-Nikpour MR, Mahmodlou R, Arjmand N, Rezaei Y. Clinical Outcomes of Myasthenia Gravis with Thy-moma and Thymic Hyperplasia Undergoing Extended Transsternal Thymectomy: A Single-Center Experience. N Am J Med Sci 2015; 7(11): 503–8.

Akaishi T, Suzuki Y, Imai T, Tsuda E, Minami N, Nagane Y. Response to treatment of myasthenia gravis according to clini-cal subtype. BMC Neurol 2016; 16(1): 225.

Liu CW, Luo M, Mei JD, Zhu YK, Pu Q, Ma L, et al. Perioper-ative and long-term outcome of thymectomy for myasthenia gravis: comparison of surgical approaches and prognostic anal-ysis. Chin Med J (Engl) 2013; 126(1): 34–40.

Koppitz H, Rockstroh JK, Schüller H, Standop J, Skowasch D, Mül-ler-Hermelink HK, et al. State-of-the-art classification and mul-timodality treatment of malignant thymoma. Cancer Treat Rev 2012; 38(5): 540–8.

de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44(1): 123–30.

Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105(4): 546–51.

Thomas CR, Wright CD, Loehrer PJ. Thymoma: state of the art. J Clin Oncol 1999; 17(7): 2280–9.

Couture MM, Mountain CF. Thymoma. Semin Surg Oncol 1990; 6(2): 110–4.

Weis CA, Yao X, Deng Y, Detterbeck FC, Marino M, Nicholson AG, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol 2015; 10(2): 367–72.

Rosenow EC 3rd, Hurley BT. Disorders of the thymus. A re-view. Arch Intern Med 1984; 144(4): 763–70.

Morgenthaler TI, Brown LR, Colby TV, Harper CM Jr, Coles DT. Thymoma. Mayo Clin Proc 1993; (11): 1110–23.

Welsh JS, Wilkins KB, Green R, Bulkley G, Askin F, Diener-West M, et al. Association between thymoma and second neo-plasms. JAMA 2000; 283(9): 1142–3.

Souadjian JV, Silverstein MN, Titus JL. Thymoma and cancer. Cancer 1968; 22(6): 1221–5.

Pan CC, Chen PC, Wang LS, Chi KH, Chiang H. Thymoma is associated with an increased risk of second malignancy. Cancer 2001; 92(9): 2406–11.

Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20(12): 1645–54.

Marom EM. Advances in thymoma imaging. J Thorac Imaging 2013; 28(2): 69–80; quiz 81–3.

Sadohara J, Fujimoto K, Müller NL, Kato S, Takamori S, Ohkuma K, et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol 2006; 60(1): 70–9.

Detterbeck FC, Zeeshan A. Thymoma: current diagnosis and treatment. Chin Med J (Engl) 2013; 126(11): 2186–91.

Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4(7): 911–9.

Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, et al. Prognostic impact of tumour size in completely resected thymic epithelial tumours. Eur J Cardiothorac Surg 2016; 50(6): 1068–74.

Kaufman AJ, Flores RM. Minimally invasive thymectomy for thymoma: does surgical approach matter or is it a question of stage? J Thorac Dis 2016; 8(12): E1711–4.

Di Crescenzo VG, Napolitano F, Panico C, Di Crescenzo RM, Zeppa P, Vatrella A, et al. Surgical approach in thymectomy: Our experience and review of the literature. Int J Surg Case Rep 2017; 39: 19–24.

Margaritora S, Cesario A, Cusumano G, Meacci E, D'Angelillo R, Bonassi S, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010; 89(1): 245–52.

Müller-Hermelink HK, Marx A. Thymoma. Curr Opin Oncol 2000; 12(5): 426–33.

Okumura M, Miyoshi S, Fujii Y, Takeuchi Y, Shiono H, Inoue M, et al. Clinical and functional significance of WHO classifica-tion on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol 2001; 25(1): 103–10.

Nichols FC, Trastek VF. Standard thymectomy. In: Shields TW, LoCicero J, Reed CE, Feins RH, editors. General thoracic sur-gery. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 2278–83.

Wang F, Pang L, Fu J, Shen Y, Wei Y, Tan L, et al. Postopera-tive survival for patients with thymoma complicating myas-thenia gravis-preliminary retrospective results of the ChART database. J Thorac Dis 2016; 8(4): 711–7.

Filosso PL, Evangelista A, Ruffini E, Rendina EA, Margaritora S, Novellis P, et al. Does myasthenia gravis influence overall sur-vival and cumulative incidence of recurrence in thymoma pa-tients? A Retrospective clinicopathological multicentre analy-sis on 797 patients. Lung Cancer 2015; 88(3): 338–43.

Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stag-es. Cancer 1981; 48(11): 2485–92.

Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994; 44(5): 359–67.

Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignan-cies: clarification and definition of terms. J Thorac Oncol 2011; 6(7 Suppl 3): S1710–6.

Detterbeck F. Towards a TNM based prognostic classification for thymic tumors. J Thorac Oncol 2013; 8(Suppl 2): S68.

Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011; 6(Suppl 3): S1698–704.

Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003; 76(3): 878–84.

Weis CA, Yao X, Deng Y, Detterbeck FC, Marino M, Nicholson AG, et al. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol 2015; 10(2): 367–72.

Carillo C, Diso D, Mantovani S, Pecoraro Y, De Giacomo T, Ciccone AM, et al. Multimodality treatment of stage II thymic tu-mours. J Thorac Dis 2017; 9(8): 2369–74.

Yan J, Liu Q, Moseley JN, Baik CS, Chow LQ, Goulart BH et al. Adjuvant Radiotherapy for Stages II and III Resected Thy-moma: A Single-institutional Experience. Am J Clin Oncol 2016; 39(3): 223–7.

Wright CD, Wain JC, Wong DR, Donahue DM, Gaissert HA, Grillo HC, et al. Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J Thorac Cardiovasc Surg 2005; 130(5): 1413–21.

Margaritora S, Cesario A, Cusumano G, Lococo F, Porziella V, Meacci E, et al. Single-centre 40-year results of redo operation for recurrent thymomas. Eur J Cardiothorac Surg 2011; 40(4): 894–900.

Chen YD, Feng QF, Lu HZ, Mao YS, Zhou ZM, Ou GF et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 2010; 78(5): 1400–6.

Hamaji M, Allen MS, Cassivi SD, Nichols FC 3rd, Wigle DA, Deschamps C, et al. The role of surgical management in recur-rent thymic tumors. Ann Thorac Surg 2012; 94: 247–54; dis-cussion 254.

Laperuta P, Napolitano F, Garzi A, Amato B, Vatrella A, Di Crescenzo V. Extrathoracic recurrence of type A thymoma. Int J Surg 2014; 12(Suppl 1): S16–8.

Huang J, Rizk NP, Travis WD, Seshan VE, Bains MS, Dycoco J, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 2007; 134(6): 1477–83.

Modh A, Rimner A, Allen PK, Greenfield B, Marom EM, Rice D, et al. Treatment Modalities and Outcomes in Patients With Advanced Invasive Thymoma or Thymic Carcinoma: A Retro-spective Multicenter Study. Am J Clin Oncol 2016; 39(2): 120–5.

Guerrera F, Rendina EA, Venuta F, Margaritora S, Ciccone AM, Novellis P, et al. Does the World Health Organization histolog-ical classification predict outcomes after thymomectomy? Re-sults of a multicentre study on 750 patients. Eur J Cardiotho-rac Surg 2015; 48(1): 48–54.

Boothe D, Orton A, Thorpe C, Kokeny K, Hitchcock YJ. Postopera-tive Radiotherapy in Locally Invasive Malignancies of the Thymus: Patterns of Care and Survival. J Thorac Oncol 2016; 11(12): 2218–26.

Lim YJ, Kim E, Kim HJ, Wu HG, Yan J, Liu Q, et al. Survival Impact of Adjuvant Radiation Therapy in Masaoka Stage II to IV Thymomas: A Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys 2016; 94(5): 1129–36.

Girard N. Chemotherapy and targeted agents for thymic ma-lignancies. Expert Rev Anticancer Ther 2012; 12(5): 685–95.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade ac-tivate non-redundant immune mechanisms in cancer. Nature 2015; 520(7547): 373–7.

Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 2014; 46(3): 361–8.

Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, et al. The IASLC/ITMIG Thymic Epithelial Tu-mors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 2014; 9(Suppl 2): S65–72.

Objavljeno
2021/08/19
Broj časopisa
Vol. 77 Br. 2 (2020): Vojnosanitetski pregled
Rubrika
Originalni članak